Photo/Zhang Jian (NBD)
1. Tesla Begins Pushing FSD V12 Self-Driving System to Employees
According to a report from Bloomberg, Tesla has begun rolling out the FSD V12 update to employees. This is one of the most significant updates to Tesla's self-driving system. Musk described it as "end-to-end AI," using a "vision input, control output" approach similar to the way the human brain makes decisions.
This is a major breakthrough for Tesla in the self-driving space and a challenge to traditional automakers. The end-to-end AI approach could lead to more reliable and safe self-driving cars.
2. Global First CRISPR Therapy Could Be Approved by FDA in Early December
A CRISPR gene editing therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics called examglogene autotemcel (brand name Casgevy) is expected to be approved by the U.S. Food and Drug Administration (FDA) in early December. The therapy is for patients with sickle cell disease. If approved, it would be the first therapy approved to use CRISPR, a gene editing technology that can be used to cut and modify DNA sequences.
CRISPR therapies have the potential to treat diseases that cannot be treated with drugs or surgery, giving hope to patients with rare diseases. Approval of this therapy would open the door to further development and application of gene editing technology, and it would bring new opportunities and challenges to the healthcare industry.
3. Musk: Manufacturing Cost of Optimus Robot Will Be Lower Than a Car
In a recent interview with MIT scientist Lex Fridman, Musk discussed his human-shaped robot, Optimus. He said that the robot's design and manufacturing methods will be similar to those used for cars, and that the cost of manufacturing Optimus will eventually be lower than that of a car. He also said that Optimus' fingers are being carefully designed with the goal of being able to pick up a needle and thread and thread it through a needle eye. He estimates that it will take about a year to achieve this goal.
This is a bold prediction from Musk about the cost of manufacturing Optimus, and it could be a major boost for the artificial intelligence and robotics industries.
4. OpenAI's Mysterious "Q" Project Sparks Industry Discussion
Reports that OpenAI's "Q*" project may be related to the ouster of CEO Sam Altman have sparked industry discussion. AI scientist Nathan Lambert speculated that "Q*" is likely about thought trees and process reward models, and it could also be related to world models. Turing Award winner Yann LeCun believes that one of the main challenges to improving the reliability of large language models is to use planning strategies instead of autoregressive token prediction, and that "Q*" is likely OpenAI's attempt in the planning domain.
This project has sparked widespread discussion and attention from within and outside the industry about OpenAI's future strategy, products, risks, and impact. It could also influence the thinking of other AI companies in the planning domain.
The content and data in this article are for reference only and do not constitute investment advice. Please verify before using. Risks are assumed by the user if any actions are taken based on this article.